MLI Stock Chart & Stats
€109.00
€0.50(0.59%)
At close: 4:00 PM EDT
€109.00
€0.50(0.59%)
Day’s Range― - ―
52-Week Range€60.50 - €126.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€642.69M
Enterprise Value€703.77M
Total Cash (Recent Filing)€30.70M
Total Debt (Recent Filing)€101.36M
Price to Earnings (P/E)149.6
Beta0.90
Next Earnings
Nov 05, 2026EPS Estimate
2.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.86
Shares Outstanding5,595,869
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)2.62
Price to Sales (P/S)1.96
P/FCF Ratio12.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)9.1
Revenue Forecast (FY)€227.14M
Bulls Say, Bears Say
Bulls Say
Recurring Calibration GrowthCalibration Solutions' 7.6% YoY growth and recurring service-driven revenue indicate a durable contribution anchored in scheduled customer needs. This mix can support visibility and repeat purchasing, while the segment's 350-basis-point gross-margin expansion strengthens its role in the portfolio.
Strong Cash Generation And DeleveragingStrong operating and free cash flow give Mesa internal funding capacity for reinvestment and debt reduction. The 31% free-cash-flow increase, alongside an $8.7M quarterly paydown and lower leverage, improves resilience and supports management's focus on higher-return businesses.
Margin ExpansionGross margin reached 64.9%, up about 290 basis points, while adjusted operating income rose 16.5%. Margin expansion across most divisions suggests operational improvement and mix benefits that can support earnings quality if maintained through ongoing portfolio execution.
Bears Say
Thin And Volatile ProfitabilityTTM net margin of about 1.9% remains thin despite positive operating profitability, and the company has recorded meaningful historical volatility including a large FY2024 loss. This leaves less room for execution setbacks and makes durable earnings conversion less established.
SDC Fulfillment Execution RiskSDC, 41% of quarterly revenue, saw organic revenue fall 3.6% because missed ship dates impaired delivery reliability. Episodic backlog improvement and renewed slippage can make revenue uneven, weaken customer loyalty, and pressure results in a major business line.
China Clinical Genomics HeadwindsClinical Genomics declined about 7% in China, and management described structural headwinds despite reducing exposure. Continued regional weakness can weigh on segment growth and limit the benefits of improvement elsewhere, making the portfolio's recovery less uniform.
Mesa Laboratories News
MLI FAQ
What was Mesa Laboratories’s price range in the past 12 months?
Mesa Laboratories lowest stock price was €60.50 and its highest was €126.00 in the past 12 months.
What is Mesa Laboratories’s market cap?
Mesa Laboratories’s market cap is €642.69M.
When is Mesa Laboratories’s upcoming earnings report date?
Mesa Laboratories’s upcoming earnings report date is Nov 05, 2026 which is in 10 days.
How were Mesa Laboratories’s earnings last quarter?
Mesa Laboratories released its earnings results on Aug 10, 2026. The company reported €2.392 earnings per share for the quarter, beating the consensus estimate of €2.343 by €0.049.
Is Mesa Laboratories overvalued?
According to Wall Street analysts Mesa Laboratories’s price is currently Overvalued.
Does Mesa Laboratories pay dividends?
Mesa Laboratories does not currently pay dividends.
What is Mesa Laboratories’s EPS estimate?
Mesa Laboratories’s EPS estimate is 2.04.
How many shares outstanding does Mesa Laboratories have?
Mesa Laboratories has 5,595,869 shares outstanding.
What happened to Mesa Laboratories’s price movement after its last earnings report?
Mesa Laboratories reported an EPS of €2.392 in its last earnings report, beating expectations of €2.343. Following the earnings report the stock price went down -0.571%.
Which hedge fund is a major shareholder of Mesa Laboratories?
Currently, no hedge funds are holding shares in DE:MLI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mesa Laboratories Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
DE:MLI Sentiment 100%
Sector Average 65%
Sector Average 65%
Insider Transactions
Bought Shares
Worth €91.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
64.58%
12-Months-Change
Fundamentals
Return on Equity
2.59%
Trailing 12-Months
Asset Growth
-3.79%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Mesa Laboratories
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment’s products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
MLI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced clear operational progress and improving financial metrics (modest revenue growth, margin expansion, AOI improvement, strong cash flow and debt reduction) with material execution challenges in SDC (quarterly revenue decline, delivery reliability and backlog volatility) and some non-operating volatility from currency impacts. Management presented a concrete remediation plan (operations focus, R&D reprioritization for Gyrolab, new commercial leadership in BPD) and committed to delivering full-year guidance in November, suggesting confidence in a fixable path forward.View all DE:MLI earnings summaries